March 12, 2018 / 10:32 AM / 9 months ago

BRIEF-Merrimack Strengthens SHERLOC Study Of MM-121 In Non-Small Cell Lung Cancer

March 12 (Reuters) - Merrimack Pharmaceuticals Inc:

* MERRIMACK STRENGTHENS SHERLOC STUDY OF MM-121 IN NON-SMALL CELL LUNG CANCER

* MERRIMACK PHARMACEUTICALS INC - ‍RANDOMIZED PHASE 2 STUDY ACCRUAL RAISED TO 100 PATIENTS; DATA STILL EXPECTED LATER THIS YEAR​

* MERRIMACK PHARMACEUTICALS INC - ‍MERRIMACK CONTINUES TO ANTICIPATE TOP-LINE DATA FROM SHERLOC STUDY IN SECOND HALF OF 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below